Epicrispr Biotechnologies, a South San Francisco-based biotech company, has announced two major advancements in its mission to develop transformative therapies for genetic diseases. The company secured $68 million in Series … Continue reading Epicrispr Biotechnologies achieves milestones in developing groundbreaking therapy for FSHD